outlook and Financial closing our you call and for our I quarter, business in quarter our and outlined addressing earlier update XXXX during the will I we Chief press this answers. remarks progress discuss first the for made Officer, have first to our performance financial and earnings three will release. we results our corporate earnings morning, two priorities issued who then the Today, start by first then will before over open review first including call. joining across Thank releases press that quarter XXXX, our as Sprague, turn the questions I we John call quarter for our provide
of Biomedical for panel, Authority, and Response, release or Human issued Administration Department XXX(k) FDA BARDA. Strategic product we collaboration for Advanced Services, U.S. with the we Development Research a that announcing and an morning, in developed Preparedness This Health TXBiothreat the a press submission and
protect U.S. both recently an sensitivity including occurring over Americans from commitment important blood demonstrated Biothreat the deliberate high that milestone XXX from the evaluation in of submission of and to positive completed or naturally clinical our negative samples federal specificity, threat XXX contrive follows subjects. healthy samples and outbreaks FDA marks and very The and pathogens,
Typhus. of and panel CDC, automated Prevention, the to on pathogens U.S. If the for treated or Tularemia, and the XX%. direct-from-blood organisms fully identified Control is infections these cause can promptly, by TXBiothreat The threats a Disease designed simultaneously TXDx run XX% and to Glanders instrument biothreat six that test FDA-cleared detects as pathogens, rates mortality including in Anthrax, with biothreat Plague not result Centers
is product appropriately to TXBiothreat blood direct-from-blood the government company, panel. we X multi-target panel the factor is will these able The have U.S. treat with such from procurement think TXBiothreat by and within directly the clinicians for in specificity biothreat sensitivity product which high very demonstrates biothreat important discussions a and with only developed the the and a of regarding U.S.-owned an We the panel provide TXBiothreat infected hours pathogens needed patients. detect to believe information
maximize strategic firm This consideration, careful issued No has sale program. on of also that company an range evaluation assets, than morning, potential a to of value, period Directors the of during strategic including and on engaged be provided merger, the maximizing release exploration process press Board are merger, reverse combination, and updates has the the is appropriate concluded value, expected required. restructuring explore transactions. disclosure licensing acquisition, other or the less After of of alternatives we an a to a other business implementation alternatives the strategic all advisory announcing and focused to
new company's while by which continuing and commercial program better opportunities the the operating the reduction incremental reduce all I context customers, priorities. pursue position and of restructuring company restructuring designed pipeline strategic things, costs three includes, support capital XX%, to preserve explore to changes advance further is program being strategic and development. corporate alternatives, other of The A its implemented was nearly is among to our will completed in discuss an workforce strategic annual last week. to
and has of improves Turning fundamentally business The around practiced through mission culture position TX the patients Biosystems independent progress. company world. to our recent of for to achieved that medicine the way is the key diagnostics the change that team lives a number recently milestones our transformative success support
These sales, corporate accomplishments our advancing support pipeline. accelerating priorities: our three our our enhancing operations and
first sales. accelerating our our priority, with Starting
increasing on sales is with instruments. on expanding products, TXDx focused of FDA-cleared the our and panels emphasis our FDA-cleared Our base sepsis commercial the test adoption increasing of strategy our of installed
we sepsis test top revenue, we test during our with earnings our the XXXX call, As of changes to strategy. will increasing our customers. priority sales be use panels hospital commercial increasing stated March two To existing sepsis drive our important made
expanding sales have include larger that achieving utilization to of hospitals higher of and those our test likelihood annualized a sepsis of our The first targets $XXX,XXX. consists panel change target
of our TXCandida of for Larger require complex that patients panels, provides increased to access greater the their balancing have At treatments. and larger increased of shown long-term we hospitals smaller sustained same targets that hospitals for hospitals have growth. our opportunity cycles, large and our TXBacteria volume given greater sales acknowledge the number use funnel larger targets of complement but time, with sales potential patient hospital number current critical and believe a
with the time of heavily as as patient accounts our sales revenue to more compared contract is our is the test accelerate from compensation change this with goes incentive of weigh hospital consists when time second The to to signed strategy legacy to well plan more with Ultimately, instrument when an instruments. to live as on spent sepsis shifting testing. intended align
and medical sepsis realize ensure products. to provide we their to economic ramp and commercial, training and can benefits offered our by the education the Our with affairs utilization integrated teams customers closely are support required and clinical
to prior year lower million the in by $X driven revenue. we product and period, During the sepsis related first quarter, instrument of million achieved revenue $X.X compared
the also increase of order. test to the an with $X.X revenue a sepsis able sepsis sepsis We the quarter increase representing we despite have prior with to March of test compared first the ended would panel period, ending year panel of panel clear Had backorder million, XX, $XXX,XXX. year generated quarter to order the test We been back been period. a $XXX,XXX back prior as XX% the compared XX%
States increase sales panel the of all instruments in We first of XX% a entered Importantly, during to results TXBacteria U.S. change the five into we with prior these commercial in the sales on globally, panel are representative focus United increasing year of more legacy the hospitals TXDx longer test strategy increased of in We the accounts for believe outside quarter, larger of including compared and market contracts utilization our sold XXX% by to cycles. which market. were period. sepsis
revenues online our commercial the in XXXX instrument TXBacteria our was that accounts XXXX year faster supported quarter timeline. period. new than the Panel more of new closes a Panel in first validation is the TXBacteria adoption ordering quarter of of four fourth our by first time, This U.S. bringing the hospital strategy strong A doubled compared to prior for the
product, as the We're of increased in the of more legacy the demand as accounts. pleased the evidenced realizing Panel with the our hospitals TXBacteria by adoption rates value are
months. to and to coming U.S. for conversion laboratories sepsis COVID-XX inform also that hospital from were sepsis panels. we initially first We which have sepsis sold instruments panels the TXDx the testing targeting in pleased approximately test of for our are that to in XX we instrument expect test converted conversions another our XXXX, you was COVID-XX during to and quarter additional I'm
into and recently systems, hospitals. two agreements two U.S. Biosystems experiencing each our we of positive sepsis covering total TX users that In are U.S. large sepsis multiyear Separately, and panels of panels. into clinical we're hospitals, The with protocols, the economic multiyear are benefits. of improved health excited they're entered sepsis in pricing hospitals test a systems integrated management XX these key health those benefits
test instruments. for The XX Panel We're are of with across initial new TXDx expand pricing and TXCandida the expanding hospitals period to TXBacteria commercial procure U.S. to of excited the use these certainly two increasing sepsis as tenets our these and and within our within growth top strategy systems as hospitals broadly priorities. large Panel sepsis an well utilization for systems, provide represent X-year opportunity the health the options about agreements core contracted U.S. health products existing
distributor continues to is TXDx This significant for there our reflected by opportunity international instruments and Internationally, a of partners. test be sepsis panels commercial our instruments to panels. sales sepsis test continued and
Europe continue the across distribution Pacific to months. see in East region the coming continue to demand expect in and strong and the We to expand Asia Middle
and of extend highlighting Scientific our of presented Clinical Our of real-world benefits the efforts experience, clinical test the ESCMID. sepsis and key opinion Board. panels. delivered team, Microbiology Three at by to Disease, leaders, by presentations the and medical benefit the Infectious were of test clinicians April, awareness instrument beyond or their In Society clinical speed, team, affairs data commercial activities and we TXDx panels European accuracy our Advisory increase our including sepsis delivered
quarters. the benefits sales ability the TX us to confidence our the technology, Driving commercial accelerate in with coming optimized our of awareness of in game gives combined plan,
XXX operating to company. have across is second to compared employees reduce success. are May leaner long-term operations XXX our taken in efficient we drive organization to our to recognize greater a measures the as that Biosystems of Moving with critical enhancing efficiency, priority, our now We To employees operations. expenses XXXX. TX
net cost We XXXX. measures cash reduce control burn to reduction expect significantly and of workforce throughout the quarterly result our our
hard to organization. greater as managing utilization. volumes, sepsis to higher continue as across margins. continually overhead drive carry focus customers process greater We the panels expansion demand increased is gross a Driving support and our allocated our operations contribution achieve test be increase improving efficiency. our leverage supply test unit can our and will which constant manufacturing work, And we volume, test increase teams product to significant at To for are for chain manufacturing Test lead growing the margin panels gross our sepsis our a can margin. panel improved
new issue inspection during quarter. and months, ability the of to March several manufacture chain supply we Operations call, our discussed test leadership. identified XXXX sufficient issue routine new hiring our our limiting team Vice product in-process and Over Considering On we quality by our was strengthened demand. last this President customer manufacturing raw we've hired of internal volume we our material subsequently operations meet to inspection, panels a products. that that that during shipped TXResistance sepsis Panel identified Panel a the resolved affected. report shipment We're $XXX,XXX of customers for expect was materials second before the for or TXBacteria TXCandida returning first the not patterns pleased and to have earlier, end end and quarter, issue referenced we more that since We're we're and the for to to we still have the Panel it cleared distributors these normalized order of through we the the working the to back
in the last be expenses in our balance first raising continue that million leverage the consistent quarter, and Finally, we by quarters increase operating our we operating gross coming extend In proceeds. our with disciplined sheet and implemented the strengthened will our cash workforce reduction with to we week, to $XX runway.
to our to priority, company the addressable TX advancing technology the and Biosystems' in pipeline. Moving platform our novel markets position expand third our future. expertise scientific
Instrument; and Our focused to next-generation one, the two test instrument tests a panel. TXDx expand two, developing pipeline new developing sepsis and menu product goals: is new on on comprehensive the
the a and Panel, to menu testing adoption FDA-cleared developing the clinicians menu new panel TXLyme solution test TXResistance Panel, on harmful products to auris test rapidly therapy. the faster our potentially the new five and both pathogens believe baumannii. currently to TXBiothreat the Panel, allow We TXDx differentiated and identify expand Acinetobacter test Each test instrument will targeted or Candida increase Instrument, including utilization. expanding represents achieve We're
remaining in focus programs. the As my we four on menu the panel discuss call, TXBiothreat the earlier comments expansion I'll
infections the is Panel XX resistance carbapenems, designed X wait resistance from molecular genes need test to vancomycin. to direct simultaneously just hours, blood and as a in The known TXResistance methicillin under antibiotic to positive diagnostic may blood cause without CE which resistance genes Panel, in detect First, antibiotic-resistant common to confer Mark, and culture. days such antimicrobials, to that a detects Europe marketed is TXResistance for sold X
XX% the completion nearly our We and have plan to completed study. FDA to the file patient advanced and upon enrollment the U.S. clinical of trial submission of
contract TXResistance granted the was for has with FDA, review upon breakthrough designation our and funding the provides which reminder, received a prioritized submission a by under device As BARDA. Panel
and intended Panel Panel direct-from-blood test is the the Lyme Second, detect the with is to the major TXLyme of TXLyme The that Borrelia bacteria burgdorferi, individuals a diagnostic United States. signs of to symptoms test cause aid is that disease provide over molecular disease of post-infection. in body Lyme can will currently requires in early advantage recommended the X create testing of the weeks which a we the significant presence and X to serological and it to diagnosis the disease, believe take Lyme antibodies,
named our partnership award Department U.S. Lyme between XXXX, Services Panel for of Innovation the a plans Cohen to winners. of award future & LymeX, and or TXLyme Accelerator, to In Human total Lyme the and the winner was million public-private Steven the $X up partnership a that largest Alexandra in to a disease Health Foundation,
We from previously FDA. Panel. in device also the And prioritized a the breakthrough received granted XXXX, upon designation covering allowing to and TXLyme the for submission for Trademark a TXLyme review patent Patent U.S. FDA the Office, Panel process
commercialization preliminary a per trial developed for test as initiate support completed level detection, We TXLyme the development LOD, TXLyme ml. laboratory early and X We and commence CFU of or established a the clinical clearance. to have submission assay the FDA of subsequently U.S. panel plan a of for to Panel
up plan to serious our XX% diagnostic Candida threat, CDC with treatment. add test standard recognized multidrug-resistant we by to a lead of a Candida over molecular inappropriate CDC, auris to Third, TXCandida difficult health methods, a pathogen Candida XX%. auris to According to can bloodstream mortality is a Candida to rate laboratory as is detects identify the infections. auris Panel, that which global direct-from-blood with
And resistant three of available to antifungals. some strains all are classes
Panel called fungal life-saving continuing health public billion are strengthen more early the high panel, The customers. awareness associated proposition even significant time test hospital provide is professionals CDC the and diseases the our annually compared detection estimates believe raise general attractive of of TXCandida the by of and with to to $XX it Candida value disease will proper adding and treatment. the to on methods existing costs We advantage as a burden other blood auris to lower in U.S. fungal our making of to as benefits culture-based
recently development completed applied device pleased FDA that to feasibility Candida I'm designation of test. for detect auris a and this the We've and early for recently also test diagnostic pathogen, report to breakthrough we
Acinetobacter test pathogens bloodstream direct-from-blood have from reported, to to which patients, the XX% critically ICU Finally, transient mortality of diagnostic can Panel, a the the we plan to Acinetobacter septic shock, ill add can on TXBacteria infections, cause molecular expand range to bacteremia test benign a detected to in baumanni rate baumannii of crude as panel. number especially to and XX%.
States occur rarely can or treatment. carbapenems, infections immune can rapid weakened targeted those importance including detection and antibiotics, healthcare antimicrobial lung of disease Acinetobacter the chronic Acinetobacter resistant outside many settings in disproportionately of diabetes. systems, United highlighting to and the with impact be
test single panel. antibiotic the a instrument direct-from-blood the a greater hours. test focused genes Looking next-generation result than bloodstream new threats caused sepsis is identified panel developing ahead at time test a is funded single a designed under a including on contract infections longer-term and sepsis test CDC Candida next-generation been and instrument in instrument we're and products, to test panel from and species, a by The our as comprehensive have sepsis comprehensive to by to of resistance increase all with XX% comprehensive detections designed approximately BARDA. sample. of bacterial X of sepsis with The The whole projects, next-generation detect blood number
milestones XB. in Option Option after the operating BARDA all been and phase, have the Option We successfully under X contract, meeting XA development of X, base Option
timing U.S. to resume the with for the additional Panel. We no-cost BARDA TXResistance revenue time BARDA's under X of we're X not is potential from to Option and a uncertain, funding contract. trial have still Option time. the BARDA on complete X following Considering the filed are this of completion guidance providing Option may clinical at funding BARDA exercise of and Further extension allow
John? call the turn Sprague first financial to for and detailed now on outlook our I'll to that, update XXXX. our provide financial With over quarter John results a
